Prenetics Global Limited Q4 FY2025 Earnings Call
· Earnings call transcript and AI-powered summary
Company Overview
- 2025 was described as the most transformative year in Prenetics’ history, with a strategic pivot toward becoming a pure-play consumer health company.
- Record full-year revenue of $92.4 million, up 480% year-over-year from 2024, driven primarily by the explosive success of IM8.
- Strong balance sheet with $171.1 million in adjusted liquid assets as of February 15, 2026, and zero debt.
- Clear path to adjusted EBITDA profitability by Q4 2027.
Strategic Actions & Corporate Transformation
- Divested three noncore businesses:
- ACT Genomics sold for $72 million in June 2025, with $46 million cash returned to Prenetics.
- Europa business exited in January 2026 via an all-stock $30 million deal.
- Insighta 35% stake sold to Tencent for $70 million, with $69 million already received.
- Bitcoin investment strategy discontinued; current holdings frozen at 510 BTC.
- Board change: Andy Cheung resigned; Dr. Darshan Shah appointed, bringing longevity and performance expertise.
IM8 Growth Highlights
- IM8 reached a $120 million annualized revenue run rate within its first year—one of the fastest recorded in the global supplement category.
- Quarterly revenue progression: from $6 million in Q1 to $27.4 million in Q4 2025.
Continue Reading
Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.
Upgrade to ProfessionalContinue Reading
Unlock the full earnings call transcript with speaker labels and formatted dialogue.
Upgrade to Professional